Literature DB >> 6386891

Distribution and concentration of cyclosporin in human blood.

K Atkinson, K Britton, J Biggs.   

Abstract

In patients receiving cyclosporin to minimise graft versus host disease after allogeneic bone marrow transplantation, whole blood cyclosporin concentration was roughly twice the serum concentration when blood was separated at 37 degrees C. In turn, blood separation at 37 degrees C resulted in a doubling of serum cyclosporin concentration compared with separation at room temperature. In vitro studies showed that the latter phenomenon was due to a temperature dependent partitioning of cyclosporin between plasma and red cells, such that increased cyclosporin was taken up from the serum into red cells at room temperature. Increasing delay in separation of patient blood (at either temperature) resulted in a gradually increasing cyclosporin serum concentration. Further in vitro studies showed that a distribution equilibrium between blood components was reached within 30 min incubation. Red cell uptake of cyclosporin was saturable at an incubation concentration of greater than 4 microgram/ml, while plasma and mononuclear cells showed a linear uptake to 7 micrograms/ml. The cellular cyclosporin content of a mononuclear cell was roughly 1000 times greater than that of an erythrocyte. For clinical monitoring we recommend the measurement of cyclosporin concentration either in whole blood or in serum separated at 37 degrees C without delay after venepuncture.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386891      PMCID: PMC498960          DOI: 10.1136/jcp.37.10.1167

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.

Authors:  B A Reitz; J L Wallwork; S A Hunt; J L Pennock; M E Billingham; P E Oyer; E B Stinson; N E Shumway
Journal:  N Engl J Med       Date:  1982-03-11       Impact factor: 91.245

2.  Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia.

Authors:  J M Hows; S Palmer; E C Gordon-Smith
Journal:  Transplantation       Date:  1982-04       Impact factor: 4.939

3.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

4.  Stability of cyclosporin A in human serum.

Authors:  J M Smith; J M Hows; E C Gordon-Smith
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

5.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

6.  Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

Authors:  K Atkinson; J C Biggs; J Hayes; M Ralston; A J Dodds; A J Concannon; D Naidoo
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

7.  Inhibition of T-cell activity by cyclosporin A.

Authors:  L Andrus; K J Lafferty
Journal:  Scand J Immunol       Date:  1981-05       Impact factor: 3.487

8.  Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients.

Authors:  A J Barrett; J R Kendra; C F Lucas; D V Joss; R Joshi; P Pendharkar; K Hugh-Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-17

9.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  6 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Characterization of cyclosporine A uptake in human erythrocytes.

Authors:  C Reichel; M von Falkenhausen; D Brockmeier; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

6.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.